



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

Monday, May 2, 2016

18:00 - 19:30

PP01: Poster Mixer and Poster Discussion Session 1

Room: Hall 3

Moderators: Michael Peake, United Kingdom & Sam Armato, USA & Kevin Blyth, United Kingdom & Marie Claude Jaurand, France & Faheez Mohamed, United Kingdom & Courtney Broaddus, USA & Marion MacFarlane, United Kingdom

PP01.01: Systemic Inflammation Consistently Predicts Adverse Outcome Based on Multiple Biomarkers in Patients with Mesothelioma

Michael McGettrick, Queen Elizabeth University Hospital, United Kingdom

PP01.02: An Update on DIAPHRAGM: A Prospective, Multi-Centre Study of Fibulin-3 and SOMAscan as Biomarkers in Mesothelioma

Selina Tsim, Queen Elizabeth University Hospital, United Kingdom

PP01.03: Examination of the Serum Soluble Mesothelin-Related Peptide (SMRP) Level in Patients with Malignant Pleural Mesothelioma

Taiichiro Otsuki, Hyogo College of Medicine, Japan

PP01.04: PI3-Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma

Rajani Kanteti, University of Chicago, USA

PP01.05: Early Diagnosis by Cytology Improves Survival

Anders Hjerpe, Karolinska University Hospital, Sweden

PP01.06: Low Merlin Expression and High Survivin Staining Index are Indicators for Poor Prognosis of Malignant Mesothelioma Patients

Mayura Meerang, University Hospital Zürich, Switzerland

PP01.07: MicroRNAs in Blood as Biomarker of Pleural Malignant Mesothelioma

Dario Consonni, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

PP01.08: Septin-7, Lipoma Preferred Partner and Transaldolase Discriminate Neoplastic From Preneoplastic Mesothelial Cells

Daniel Pouliquen, UMR 892 INSERM / 6299 CNRS, France

PP01.09: Col3A1, a New Potential Immunohistological Marker for the Diagnosis of Malignant Pleural Mesothelioma

Christophe Blanquart, INSERM UMR 892 / CNRS 6299, France

PP01.10: Prognostic Significance of Mitotic Arrest Deficient 2-Like Protein 1 in Malignant Mesothelioma

Aaron Mansfield, Mayo Clinic, USA

PP01.11: Brain-Derived Neurotrophic Factor (BDNF) and Fibulin-3 as Biomarkers for Diagnosis of Malignant Pleural Mesothelioma (MPM)

Sarah Benziane, Hospital of the University (CHU) of Lille, France

PP01.12: Target Trial

Duneesha De Fonseka, North Bristol NHS Trust, United Kingdom



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

- PP01.13: Ex vivo effects of Pemetrexed and Carboplatin on Malignant Mesothelioma Cells**
Carl-Olof Hillerdal, Karolinska Institutet, Sweden
- PP01.14: Diagnosing Mesothelioma via Chest Wall Motion Analysis Technology**
Ghazi Elshafie, Heartlands Hospital, United Kingdom
- PP01.15: Circulating Level of the Complement Component 4d (C4d) Correlates with Chemotherapeutic Response and Survival in MPM Patients**
Thomas Klikovits, Medical University of Vienna, Austria
- PP01.16: VOC Analysis in Headspace Air of Mesothelioma and Lung Cancer Cell Lines: A Comparative Literature Study**
Sabrina Lagniau, Ghent University, Belgium
- PP01.17: Prognostic Biomarkers in a Large Cohort of Patients with Malignant Pleural Mesothelioma - a Retrospective Two-Center Study**
Thomas Klikovits, Medical University of Vienna, Austria
- PP01.18: Changes in Monocyte Count and Lymphocyte-To-Monocyte Ratio during Induction Chemotherapy Correlate with Clinical Outcome**
Mir Hoda, Medical University of Vienna, Austria
- PP01.19: Combining Cell-Free microRNAs and SMRP: A Multi-Biomarker Signature with Improved Diagnostic Accuracy**
Michaela Kirschner, University Hospital Zurich, Switzerland
- PP01.20: Tumor-Infiltrating Lymphocytes and BAP-1, VEGFR-2, IGF-1R Expression in Malignant Pleural Mesothelioma**
Luca Ampollini, University Hospital of Parma, Italy
- PP01.21: Serum Biomarkers in Mesothelioma 1-3 Years before Diagnosis: A Pilot Study**
Oluf Røe, Norwegian University of Science and Technology, Norway
- PP01.22: Role of EPHA2 in Malignant Mesothelioma**
Yi-Hung Carol Tan, University of Chicago, USA
- PP01.23: ENOX2-Based Early Detection of Malignant Mesothelioma**
Bruce Robinson, University of Western Australia, Australia
- PP01.24: Prognostic microRNAs in Tissues from Malignant Pleural Mesothelioma Patients Receiving Multimodality Therapy**
Michaela Kirschner, University Hospital Zurich, Switzerland
- PP01.25: Chemotherapy and Chemotherapy Plus Talc Pleurodesis In Treatment of Malignant Pleural Mesothelioma: A Retrospective Analysis**
Guntulu Ak, Eskisehir Osmangazi University, Turkey
- PP01.26: Initial Results of the Multicentric Turkish Malignant Pleural Mesothelioma Database***
Hasan Batirel, Marmara University, Turkey
- PP01.27: Fourth Line Chemotherapy with Docetaxel for Malignant Pleural Mesothelioma (MPM)**
Jens Sørensen, Finsen Centre/National University Hospital, Denmark



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP01.28: Phase I Trial of Lentiviral CART-Meso Cells in Progressive Malignant Pleural Mesothelioma (MPM)

Steven Albelda, University of Pennsylvania, USA

PP01.29: Does Malignant Pleural Mesothelioma with Metastases at First Presentation Really Benefit from Chemotherapy?

Hala Aziz Shokralla, National Cancer Institute, Egypt

PP01.30: Mesothelioma Mortality in Australian and Italian-Born Workers Exposed to Blue Asbestos at Wittenoom, Western Australia

Nicholas De Klerk, University of Western Australia, Australia

PP01.31: Preliminary Report of an Observational Clinical Registry on Malignant Pleural Mesothelioma (MPM) in Italy (REGCLIN)

Federica Grosso, SS. Antonio e Biagio e C. Arrigo, Hospital, Italy

PP01.32: Slowly Progressive Malignant Pleural Mesothelioma in Aged Patients

Mizue Hasegawa, Tokyo Women's Medical University, Japan

PP01.33: A Cohort of Malignant Pleural Mesothelioma Treated and Followed in the Last Ten Years at Instituto Oncológico Henry Moore

Mariana Abal, Instituto Oncológico Henry Moore, Argentina

PP01.34: Brain Metastases in Malignant Pleural Mesothelioma

Nobukazu Fujimoto, Okayama Rosai Hospital, Japan

PP01.35: Malignant Pleural Mesothelioma in Patients Older than 45 Years

Fatma Aou El-Kasem, National Cancer Institute, Egypt

PP01.36: A Mesothelioma Cluster Amongst Experimental Physicists

Steven Kazan, Kazan McClain Satterley & Greenwood, USA

PP01.37: Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response.

Hala Aziz Shokralla, National Cancer Institute, Egypt

PP01.38: Non-epithelial Pleural Mesothelioma; Criteria, Prognostic Factors And Predictors Of Response

Hala Aziz Shokralla, National Cancer Institute, Egypt

PP01.39: Does Pretreatment Body Weight Have Any Significant Impact on Survival in Pleural Mesothelioma in Young Age Group?

Hala Aziz Shokralla, National Cancer Institute, Egypt

PP01.40: Malignant Pleural Mesotheliom: A Single-Center Experience in Croatia

Marko Jakopovic, University Hospital Center Zagreb, Croatia

PP01.41: Mesothelioma Incidence in Lombardy, Italy: Time Patterns and Future Projections

Dario Consonni, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

PP01.42: Clinico Pathological Characteristics of Young Egyptian Malignant Pleural Mesothelioma Patients

Fatma Aou El-Kasem, National Cancer Institute, Egypt



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP01.43: Increasing Age at Diagnosis in the Australian Malignant Pleural Mesothelioma Population: What Are the Potential Implications?

Matthew Soeberg, Asbestos Diseases Research Institute, Australia

PP01.44: Study on the Evolution over Time of the Risk of Mesothelioma and Lung Cancer among Former Asbestos-Exposed Workers

Corrado Magnani, University Eastern Medicine, Italy

PP01.46: Mortality/Hospitalization From Pleural Mesothelioma Associated With Environmental Exposure to Fluoro-Edenite in Biancavilla

Susanna Conti, Istituto Superiore di Sanità, Italy

PP01.47: Survival and Expected Years of Life Lost of Malignant Mesothelioma: Analysis of 105 Cases in Taiwan, 1977-2015

Lukas Lee, National Health Research Institutes, Taiwan

PP01.50: Investigating Palygorskite's Role in the Development of Mesothelioma in Southern Nevada

Michele Carbone, University of Hawaii Cancer Center, USA

PP01.51: Mesothelioma Mortality in Poland between 1999 and 2013

Anna Minkiewicz, Medical University of Warsaw, Poland

PP01.52: Relationship between Histological Type and Pleural Effusion in Malignant Pleural Mesothelioma

Koji Mikami, Hyogo college of medicine, Japan

PP01.53: Pattern Of Malignant Pleural Mesothelioma in Egyptian Patients

Fatma Aou El-Kasem, National Cancer Institute, Egypt

PP01.54: Asbestos Consumption and Pleural Mesothelioma Mortality in Poland in Comparison with Other European Countries

Anna Minkiewicz, Medical University of Warsaw, Poland

PP01.56: Blood DNA Methylation Changes in Malignant Pleural Mesothelioma

Elisabetta Casalone, Human Genetics Foundation and University of Turin, Italy

PP01.57: Malignant Pleural Mesothelioma in Africa

Gill Nelson, University of Witwatersrand, South Africa

PP01.59: Malignant Pleural Mesothelioma Long Term Survivors: A Population Based Study (LUME Study)

Valeria Ascoli, Oncological and Anatomo-Pathological Sciences, Sapienza University, Italy

PP01.60: Epidemiology of Mesothelioma in Southern Brazil: A Reality Still to Be Studied

Dario Consonni, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

PP01.61: Malignant Pleural Mesothelioma in Young People

Ahmed El Bastawisy, National Cancer Institute, Egypt

PP01.62: Malignant Pleural Mesothelioma in Austria: Data from the Austrian Mesothelioma Interest Group Database

Mir Hoda, Medical University of Vienna, Austria



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP01.63: Histopathological Reporting of Mesothelioma Resection Specimens
David Moore, University Hospitals Leicester NHS Trust, United Kingdom

PP01.64: Inherited Predisposition to Malignant Mesothelioma
Irma Dianzani, Interdepartmental Center for Studies on Asbestos and other Toxic
Particulates "G. Scansetti", Italy

**PP01.65: Characterization of Intertumor Heterogeneity in Malignant
Mesothelioma**
Noushin Nabavi, Vancouver Prostate Centre, Canada

**PP01.66: Pathology Analysis for Mesothelioma Study in the United Kingdom:
Current Practice and Historical Development**
Bruce Case, McGill University, Canada

**PP01.67: Variations in Copy Number in the Malignant Pleural Mesothelioma
Genome**
Marieke Hylebos, Center for Oncological Research, University of Antwerp, Belgium

**PP01.68: Homozygous 9p21 (p16/CDKN2A) Deletion in Mesothelioma-5 Year
Retrospective Specialist Diagnostic Pleural Pathology Audit**
Lauren Harries, University Hospital of South Manchester, United Kingdom

**PP01.69: Mutation Status and Expression of the microRNA-Processing
Ribonuclease-III Dicer1 in Malignant Pleural Mesothelioma**
Eric Santoni-Rugiu, Copenhagen University Hospital, Denmark

**PP01.70: A Comparison of the Genetic Characteristics of Murine and Human
Malignant Mesothelioma**
Sophie Sneddon, National Centre for Asbestos Related Diseases, The University of
Western Australia, Australia

**PP01.71: Mutational Burden and CDKN2A Status as a Robust Outcome Predictor
for Radical Surgery in Mesothelioma**
Annabel Sharkey, University of Leicester, United Kingdom

**PP01.72: Whole-Genome Dna Methylation and Transcriptome Changes in Asbestos
Exposed met5a Cells**
Elisabetta Casalone, Human Genetics Foundation and University of Turin, Italy

**PP01.73: Genomic Interrogation of a Clonal Recurrence of Pleural Mesothelioma
12.5 Years After Radical Surgery**
Annabel Sharkey, University of Leicester, United Kingdom

**PP01.74: CDKN2A Deletion: A Clonal Mutation in Malignant Pleural Mesothelioma
Development?**
Luke Martinson, University of Leicester, United Kingdom

**PP01.75: Update: Recent Studies Examining Impact of BAP1 Mutation on
Mesothelioma Risk and Implications for Mesothelioma Litigation**
Steven Kazan, Kazan McClain Satterley & Greenwood, USA

PP01.76: BAP1 Value in Diagnosis
Michele Carbone, University of Hawaii Cancer Center, USA

**PP01.77: A Systematic Investigation of the Maximum Tolerated Dose of Cytotoxic
Chemotherapy with Supportive Care in Mice**



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

Willem Lesterhuis, National Centre for Asbestos Related Diseases, The University of Western Australia, Australia

PP01.78: Cancer Chemo Immunotherapy - Exploiting the Immunogenic Potential of Cyclophosphamide

Willem Lesterhuis, National Centre for Asbestos Related Diseases, The University of Western Australia, Australia

PP01.79: Identification of Repurposed Drugs That Increase Immune Checkpoint Blockade Efficacy in Mesothelioma Using Network Analysis of Responding Tumours

Willem Lesterhuis, National Centre for Asbestos Related Diseases, The University of Western Australia, Australia



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

Tuesday, May 3, 2016

18:00 - 19:30

PP02: Poster Mixer and Poster Discussion Session 2

Room: Hall 3

Moderators: David Waller, United Kingdom & Noelle O'Rourke, United Kingdom & Takashi Nakano, Japan & Peter Szlosarek, United Kingdom & Paul Baas, Netherlands & Ian Woolhouse, United Kingdom & Rabab Gaafar, Egypt & Mary Hesdorffer, USA & Robert Rintoul, United Kingdom & Sanjay Papat, United Kingdom & Gary Middleton, United Kingdom

PP02.01: Art and Science: Relationship with Human Anatomy from Aesthetic and Scientific Perspectives

Guillermo Villamizar, FundClas, Colombia

PP02.02: Localized Splenic Reoccurrence in Malignant Peritoneal Mesothelioma

Yaakov Bressler, Columbia University Medical Center, USA

PP02.03: Radiological Features of Pleural Mesothelioma Compared with Cases Diagnosed before and after 2008 in Japan

Takumi Kishimoto, Okayama Rosai Hospital, Japan

PP02.04: CT Findings of Malignant Pleural Mesothelioma and Correlation with the Survival Period

Katsuya Kato, Kawasaki Medical School, Japan

PP02.05: Asbestos Body and Pleural Plaque of Patients with Malignant Pleural Mesothelioma Who Underwent Extrapleural Pneumonectomy

Kazunori Okabe, Yamaguchi Ube Medical Center, Japan

PP02.06: The Imaging Journey of a Patient with Malignant Mesothelioma

Vincent Lam, University Hospitals of Leicester, United Kingdom

PP02.07: Patterns of Detectable Tumor Progression in Patients with Malignant Pleural Mesothelioma with an FDG-PET-Negative T1a Tumor

Kozo Kuribayashi, Hyogo College of Medicine, Japan

PP02.08: Lymphangitic Carcinomatosis: A Common Form of Progression in Malignant Pleural Mesothelioma Following Radical Pleurectomy

Ian Berger, University of Pennsylvania, USA

PP02.09: Malignant Pleural Mesothelioma, Demographic Data and Clinical Staging of 193 Consecutive Patients

Amr Eldemery, National Cancer Institute, Egypt

PP02.10: Into the Deep: Closer Look at Immune Cells and Immune Checkpoint Expression in Human Malignant Pleural Mesothelioma

Elly Marcq, Center for Oncological Research, University of Antwerp, Belgium

PP02.11: Development of Novel Therapeutics Targeting Malignant Pleural Mesothelioma

Perry Devo, University of Greenwich, United Kingdom

PP02.12: Inhibition of Methyltransferase EZH2 Improves Tumoricidal Activity of Macrophages against Mesothelioma Cells



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

Malik Hamaidia, Interdisciplinary Cluster for Applied Genoproteomics (GIGA) of University of Liège, Belgium

PP02.13: The DI 922-947 Oncolytic Virus as a New Possible Therapeutic Tool against Mesothelioma

Carmelina Iannuzzi, University of Siena, Italy

PP02.14: Characterising CTL Responses against Mesothelioma Neo-Antigens

Bruce Robinson, University of Western Australia, Australia

PP02.15: Gene Profile of Mesothelioma Tumorigenesis and Initiation after Chemoradiation Treatment in vitro and in vivo Models

Licun Wu, Toronto General Hospital and Princess Margaret Cancer Center, Canada

PP02.16: The Elevated Levels of G-MDSC in Mesothelioma Patients Inhibit T Cell Proliferation and Function by ROS Generation

Raffit Hassan, National Cancer Institute, USA

PP02.17: Novel Medicinal Chemistry Approaches in Mesothelioma: The Role of Natural Products

Adrian Dobbs, University of Greenwich, United Kingdom

PP02.18: HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma

Matthew Wu, University Health Network, Canada

PP02.19: Immunophenotype of a Novel Murine Mesothelioma Cell Line RN5 and Specific Immunity Generated by Pulsation with Cell Lysate

Licun Wu, Toronto General Hospital and Princess Margaret Cancer Center, Canada

PP02.21: Focal Adhesion Kinase Inhibition Targets Macrophages in vitro and in vivo in a Mesothelioma Mouse Model

Lysanne Lievense, Erasmus MC Cancer Institute, Netherlands

PP02.22: Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression

Lysanne Lievense, Erasmus MC Cancer Institute, Netherlands

PP02.23: The Abscopal Effect of Radiotherapy in the Context of Checkpoint Blockade in a Mouse Mesothelioma Model

Alistair Cook, The University of Western Australia, Australia

PP02.26: Targeted Depletion of Regulatory T Cells in Mesothelioma

Scott Fisher, National Centre for Asbestos Related Diseases. The University of Western Australia, Australia

PP02.27: Legal Claims for Asbestosis in the Netherlands Possible since 2014: How It Works

Wanda Hagmolen Of Ten Have, Radboudumc, Netherlands

PP02.28: Evaluation of Curcumin i.p. For the Treatment of Sarcomatoid Mesothelioma, Experimental Study on a Rat Model

Daniel Pouliquen, UMR 892 INSERM / 6299 CNRS, France

PP02.29: Biphaseic Pleural Mesothelioma: Unusual Clinical Behavior

Abdulhadi Almutairi, King Fahad Specialist Hospital, Saudi Arabia



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP02.30: MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication versus No Pleurectomy Decortication
Eric Lim, Royal Brompton Hospital, United Kingdom

PP02.31: MesoTRAP: A Feasibility Study of Indwelling Pleural Catheter versus VAT Pleurectomy for Trapped Lung in Mesothelioma
Robert Rintoul, Papworth Hospital NHS Foundation Trust, United Kingdom

PP02.32: LUME-Meso: A Placebo-Controlled Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin Followed by Maintenance Nintedanib
Sanjay Papat, Royal Marsden Hospital NHS Foundation Trust, United Kingdom

PP02.33: Autologous Dendritic Cell Immunotherapy Loaded with an Allogenic Tumor Cell Lysate in Patients with Mesothelioma
Joachim Aerts, Erasmus MC Cancer Institute, Netherlands

PP02.34: Randomised Phase II Trial of Vinorelbine as 2nd-Line Therapy for Patients with Malignant Pleural Mesothelioma - VIM Trial
Lisette Nixon, Cardiff University, United Kingdom

PP02.35: A Randomized Study of Amatuximab with Pemetrexed and Cisplatin as Front-Line Therapy for Subjects with Pleural Mesothelioma
Bruce Wallin, Morphotek, Inc, USA

PP02.36: Switch-Maintenance with Gemcitabine for Patients with Malignant Mesothelioma: Feasibility of a Randomized Phase II Study
Josine Quispel-Janssen, Netherlands Cancer Institute, Netherlands

PP02.37: MESOCLIN: A French National Network of Expert Centers for the Management of MPM Patients and for Research Promotion
Arnaud Scherpereel, Hospital of the University (CHU) of Lille, France

PP02.38: Isogenic Cell Lines for Targeted Therapy Discovery in BAP1-Deficient
Zohra Butt, University of Liverpool, United Kingdom

PP02.39: Does Open Access Expert Phone Triage Based on 2012 IMiG Guidelines for Veterans Receiving Care within the VA, Alter Therapy?
Abraham Lebenthal, Brigham and Women's Hospital, USA

PP02.41: MINE PROJECT - Mesothelioma Information Network in Europe
Corrado Magnani, University Eastern Medicine, Italy

PP02.42: Personalised Support for Patients with Malignant Pleural Mesothelioma (MPM) in New South Wales, Australia
Jocelyn McLean, Asbestos Diseases Research Institute, Australia

PP02.43: Surgical Cytoreduction and Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Malignant Pleural Mesothelioma
Michael Ried, University Medical Center Regensburg, Germany

PP02.44: Diode-Pumped Nd:YAG Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma - First Experience
Servet Bölükbas, Helios Klinikum Wuppertal, Germany

PP02.45: Pathological Evaluation of the Visceral Pleura Stamp in the Radical Pleurectomy/Decortication for MPM Patients
Masashi Kobayashi, Tokyo Medical and Dental University, Japan



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP02.46: Clinical and Immunologic Impact of Surgery for Malignant Pleural Mesothelioma

Vincenzo Ambrogi, Tor Vergata University, Italy

PP02.47: Who Benefits From Macroscopic Complete Resection In Malignant Pleural Mesothelioma?

Hasan Batirel, Marmara University Faculty of Medicine, Turkey

PP02.48: Is Surgery For Mesothelioma In The UK A Dying Modality In The Management Of Malignant Mesothelioma? Update on our Experience

Mohammed Khalil, Castle Hill Hospital, United Kingdom

PP02.49: The Analysis of the Recurrence of the Patients Who Underwent Surgical Resection for Malignant Pleural Mesothelioma

Nobuyuki Kondo, Hyogo College of Medicine, Japan

PP02.50: Ipsilateral Pneumonectomy after Pleurectomy/Decortication in a Patient with Malignant Pleural Mesothelioma

Toru Nakamichi, Hyogo College of Medicine, Japan

PP02.51: Induction Chemotherapy Followed by Surgery for Malignant Pleural Mesothelioma

Nobuyuki Kondo, Hyogo College of Medicine, Japan

PP02.52: Anti-Tumor Effects of Metformin and Nutlin-3a in Malignant Pleural Mesothelioma

Yuji Tada, School of Medicine Chiba University, Japan

PP02.53: Compared High-Resolution Whole Genome Screening of Mesothelioma and Benign Asbestos Pleurisy

Tunç Tuncel, Eskisehir Osmangazi University, Turkey

PP02.54: Analysis of Gene-Expression Changes in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma

Courtney Broaddus, University of California San Francisco, USA

PP02.55: Myosin II-Dependent Cell Contractility Drives Spontaneous Nodule Formation of Mesothelioma Cells

Julia Tarnoki-Zach, Eotvos Lorand University, Hungary

PP02.56: Post-Transcriptional Regulation of Calretinin Expression

Jelena Kresoja-Rakic, University of Zürich, Switzerland

PP02.57: Identification of Cis- and Trans-Acting Elements Regulating Calretinin Expression in Mesothelioma Cells

Jelena Kresoja-Rakic, University of Zürich, Switzerland

PP02.58: Decreased Proliferation and Cell Migration of Primary Mesothelial Cells from Calretinin-Deficient (CR^{-/-}) Mice

Walter Blum, University of Fribourg, Switzerland

PP02.59: KCNMA1 Is Targeted by miR-17-5p and Modulates Cell Migration in Malignant Pleural Mesothelioma

Yuen Yee Cheng, Asbestos Diseases Research Institute, Australia



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP02.60: Engineered, Light-Controlled Growth Factor Receptors for Mesothelioma Research

Michael Grusch, Medical University of Vienna, Austria

PP02.61: Preclinical Investigation of the Therapeutic Potential of Nintedanib in Malignant Pleural Mesothelioma

Viktoria Laszlo, Medical University of Vienna, Austria

PP02.62: Comparative Analysis of 4 Experimental Mesotheliomas in F344 Rats: A Preliminary Study of Their Tumor Biology Features

Joëlle Nader, UMR 892 INSERM / 6299 CNRS, France

PP02.63: THBS2, a Novel Gene Involved in the Malignant Progression of Pleural Mesothelioma

Elisa Barone, University of Pisa, Italy

PP02.64: Growth Factor-Induced Morphology and Expression Changes in Cell Models Reflecting the Histological Mesothelioma Subtypes

Michael Grusch, Medical University of Vienna, Austria

PP02.65: The H3K27me3 Demethylase KDM6B as an Epigenetic Regulator of ER α Expression in Human Malignant Pleural Mesothelioma

Giulia Pinton, University of Piemonte Orientale, Italy

PP02.66: Combination of Nutlin-3a and HSP90 Inhibitors Produces Synergistic Cytotoxicity on Mesothelioma with the Wild-Type p53

Masatoshi Tagawa, Chiba Cancer Center Research Institute, Japan

PP02.67: Shed Syndecan-1 Alters Angiogenesis in Malignant Mesothelioma

Katalin Dobra, Karolinska Institutet, Sweden

PP02.68: Utilising MicroRNAs to Sensitise Mesothelioma to Cisplatin and Gemcitabine

Yuen Yee Cheng, Asbestos Diseases Research Institute, Australia

PP02.69: Trabectedin Is Active as Single Agent and Synergizes with Chemotherapy and Bcl-2 Inhibition in Malignant Pleural Mesothelioma

Mir Hoda, Medical University of Vienna, Austria

PP02.70: Live Cells Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Emanuela Felley-Bosco, Zürich University Hospital, Switzerland

PP02.71: Analysis of Novel RHOA Mutations in Malignant Pleural Mesothelioma

Antonios Sideris, Brigham and Women's Hospital and Harvard Medical School, USA

PP02.72: Cell Assays and SAXS Indicate That BAMLET Is a Potential Treatment for Chemotherapy-Resistant Mesothelioma

Glen Reid, Asbestos Diseases Research Institute, Australia

PP02.73: Tumour Suppressor microRNA-137-3p Targets Onco-Protein YB-1 in Malignant Pleural Mesothelioma

Thomas Johnson, Asbestos Diseases Research Institute, Australia

PP02.74: IFN Regulatory Factor 9 Play Key Role in Mesothelioma Growth

Yidan Zhao, University Health Network, Canada



iMig2016

Towards Personalized Care

MAY 1-4, 2016 BIRMINGHAM, UK

13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP

PP02.75: Pro-Oncogenic Effects of Pathogenic Fibres on Mesothelial Cells

Joaquin Zacarias-Cabeza, MRC Toxicology Unit, United Kingdom

PP02.76: 'Are the Psychological Needs of Patients with Mesothelioma the Same as Those with Advanced Lung Cancer?'

Hannah Ball, Oxford University Hospitals NHS Foundation Trust, United Kingdom

PP02.77: "Around Australia in 80 Days"

Judy Rafferty, Canberra Hospital/Lung Foundation Australia, Australia